 Home > Active Ingredient News > Antitumor Therapy > J Thorac Oncol: The efficacy of nano-paclitaxel vs docetaxel in the treatment of patients with advanced NSCLC

J Thorac Oncol: The efficacy of nano-paclitaxel vs docetaxel in the treatment of patients with advanced NSCLC

 Last Update: 2021-05-20
 Source: Internet
 Author: User

Tags

3 4 tubing

phase definition science

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The global incidence of non-small cell lung cancer ( NSCLC ) is high, and the related mortality rate remains high.

NSCLC molecular targeting

This study aims to evaluate the efficacy and safety of nanoparticle-encapsulated (nab-) paclitaxel in patients with advanced NSCLC who have previously been treated .

To evaluate the efficacy and safety of nanoparticle-encapsulated (nab-) paclitaxel in patients with advanced NSCLC who have previously been treated

This is a randomized, open-label, non-inferiority phase 3 trial that recruited patients with advanced NSCLC who had previously been treated with cytotoxic chemotherapy.

From May 22, 2015 to March 12, 2018, a total of 503 patients were randomly assigned to the treatment group: 252 in the nab-paclitaxel group and 251 in the docetaxel group.

Overall survival

The median overall survival of the nab-paclitaxel group and the docetaxel group were 16.

The median overall survival of nab-paclitaxel group and docetaxel group were 16.

Progression-free survival

The median progression-free survival of the nab-paclitaxel group and the docetaxel group were 4.

The median progression-free survival of the nab-paclitaxel group and docetaxel group were 4.

In summary, for patients with advanced NSCLC who have previously been treated, nab-paclitaxel is not inferior to docetaxel in terms of overall survival .

For patients with previously treated advanced NSCLC, nab-paclitaxel is not inferior to docetaxel in terms of overall survival.

Original source:

Yoneshima Yasuto, Morita Satoshi, Ando Masahiko et al.

org/10.
1016/j.
jtho.
2021.
03.
027" target="_blank" rel="noopener">Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non-small cell lung cancer.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Factory Supply Veliparib HCL 99% Powder CAS 912445-05-7 EGC-Veliparib HCL Price

CAS No.: 912445-05-7

Pesticide Grade

$110-115/KG FOB

Evodiamine Pharmaceutical Grade CAS 518-17-2 Evodiamine powder

CAS No.: 518-17-2

Pharmacy Grade

$90-100/KG FOB

Daunorubicin

CAS No.: 20830-81-3

$1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.